



# BETA DRUGS LIMITED

**BDL/PKL/SEC/2025**

**21<sup>st</sup> November, 2025**

National Stock Exchange of India Ltd.  
Exchange Plaza, 5th Floor  
Plot no. C/I, G Block  
Bandra-Kurla Complex, Bandra (E)  
Mumbai — 400 051.

## **SYMBOL-BETA**

**Sub.: Intimation of receipt of approval of Listing of equity shares of Beta Drugs Limited on Capital Market Segment (Main Board) pursuant to Migration from SME Emerge platform (NSE).**

**Ref: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

**Dear Sir/Madam**


Pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we would like to inform that BETA DRUGS LIMITED ("the Company") has received the approval for Listing of equity shares of Beta Drugs Limited on Capital Market Segment (Main Board) pursuant to Migration from SME Emerge platform (NSE) vide letter Ref: NSE/LIST/284, dated November 20, 2025 from National Stock Exchange of India Limited.

Please find enclosed herewith a copy of the Approval Letter of the National Stock Exchange of India Limited. We further inform you that the equity shares of Beta Drugs Limited will be effectively listed and traded on the NSE Mainboard Platform starting from **Monday, November 24, 2025**.

Kindly take the above information on record.

Thanking You

Your's faithfully  
For Beta Drugs Ltd.

Beta Drugs Limited  
  
Company Secretary  
ACS - 24684

Rajni Brar  
Company Secretary

**CIN No.:** L24230HP2005PLC028969

**Admin. Office :** SCO 184, Sector-5, Panchkula-134 114 Haryana (INDIA) Phone: +91-172-2585481-482-483

**Registered Office & Works:** Vill. Nandpur, Lodhimajra Road, Tehsil. : Baddi, Distt. Solan, H.P. Phone No. : 01795-236196

**Website :-** [www.betadrugslimited.com](http://www.betadrugslimited.com)

**E-Mail :-** [info@betadrugslimited.com](mailto:info@betadrugslimited.com)



Ref: NSE/LIST/ 284

November 20, 2025

The Company Secretary  
Beta Drugs Limited  
Village Nandpur Baddi,  
Himachal Pradesh-17410

**Kind Attn: Ms. Rajni Brar**

Dear Madam,

**Re.: Listing of equity shares of Beta Drugs Limited on Capital Market Segment (Main Board) pursuant to Migration from SME Emerge platform**

This is with reference to your application for listing and trading in equity shares of the Company on Capital Market Segment (Main Board) of the Exchange. We are pleased to inform you that the equity shares of the Company shall be listed and admitted to dealings on the Exchange (Capital Market Segment) w.e.f. November 24, 2025 pursuant to migration from SME Emerge platform as per the details given below:

Sr. No.	Description of Securities	Symbol	Series	No. of Securities	Mkt. Lot	Distinctive Numbers
1.	Equity shares of Rs.10/- each fully paid up	BETA	EQ	10094553	1	1 to 10094553

In view of the above the trading in equity shares of the Company on SME Platform (EMERGE) will be suspended with effect from November 24, 2025.

You are requested to mention the Symbol and series in all future correspondence. All important information submitted by you pursuant to the various Regulations of SEBI (LODR), 2015 shall be broadcast through our nationwide network to the trading members.

Please note that all reports, statements, intimations, documents, filings and/or any other information required to be filed by the listed entities under the respective SEBI Regulations/SEBI Circulars (as amended from time to time) shall be submitted by the Company only through 'NEAPS' – NSE Electronic Application Processing System (<https://neaps.nseindia.com/NEWLISTINGCORP/>), an online filing facility provided by the Exchange. The Exchange has hosted the contact details of the Exchange officials along with the profiles handled on NEAPS portal at Help>Contact Us.

If you require any further clarifications, we shall be glad to oblige.

**Yours faithfully,  
For National Stock Exchange of India Limited**

**Srishti Soni  
Manager**

This Document is Digitally Signed

